BIO-PATH HOLDINGS, INC. Files S-1 Registration Statement

TL;DR

<b>BIO-PATH HOLDINGS, INC. has filed an S-1 registration statement with the SEC, indicating plans for a public offering.</b>

AI Summary

BIO-PATH HOLDINGS INC (BPTH) filed a IPO Registration (S-1) with the SEC on March 8, 2024. BIO-PATH HOLDINGS, INC. filed an S-1 registration statement on March 8, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. The principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401. The filing is for registration under the Securities Act of 1933. The company was formerly known as OGDEN GOLF CO CORP, with a name change on February 5, 2001.

Why It Matters

For investors and stakeholders tracking BIO-PATH HOLDINGS INC, this filing contains several important signals. This S-1 filing signals the company's intent to raise capital through the public markets, which could fund future operations, research, or expansion. The filing provides detailed information about the company's business, financial condition, and the securities being offered, allowing potential investors to assess risks and opportunities.

Risk Assessment

Risk Level: low — BIO-PATH HOLDINGS INC shows low risk based on this filing. The filing is an S-1 registration statement, which is a preliminary step for a public offering and does not contain specific financial performance data or operational details that would indicate immediate risk.

Analyst Insight

Monitor for the effectiveness of the S-1 registration statement and subsequent announcements regarding the public offering details, including the number of shares and pricing.

Key Numbers

• 2024-03-08 — Filing Date (Date the S-1 registration statement was filed.)
• 333-277802 — SEC File Number (SEC file number associated with the registration.)
• 24735501 — Film Number (Film number for the filing.)
• 2001-02-05 — Date of Name Change (Date the company changed its name from OGDEN GOLF CO CORP.)

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant name
• March 8, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 2834 (industry_code) — Primary Standard Industrial Classification Code Number
• 87-0652870 (identifier) — I.R.S. Employer Identification Number
• 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401 (address) — Principal executive offices address
• Peter H. Nielsen (person) — President and Chief Executive Officer
• OGDEN GOLF CO CORP (company) — Former company name

FAQ

Industry Context

The company operates in the Pharmaceutical Preparations industry (SIC code 2834). S-1 filings are typically made by companies planning to offer securities to the public.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering, including the type and number of securities, and the intended use of proceeds.
2. Track the SEC's review process and any subsequent amendments or effectiveness declarations for the registration statement.
3. Analyze any future prospectus or offering documents for specific financial projections and risk factors related to the offering.

Key Dates

• 2024-03-08: S-1 Filing — Registration statement filed with the SEC, indicating intent for public offering.
• 2001-02-05: Name Change — Company formerly known as OGDEN GOLF CO CORP.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against for the current entity.

Key Financial Figures

• $0.001 — 3 shares of our common stock, par value $0.001 per share, together with warrants to pu
• $6.51 — sumed combined public offering price of $6.51 per share and one Common Warrant to pur

Filing Documents

• tm248277-1_s1.htm (S-1) — 444KB
• tm248277d2_ex4-21.htm (EX-4.21) — 93KB
• tm248277d2_ex4-22.htm (EX-4.22) — 98KB
• tm248277d2_ex4-23.htm (EX-4.23) — 101KB
• tm248277d2_ex10-39.htm (EX-10.39) — 87KB
• tm248277d2_ex10-40.htm (EX-10.40) — 177KB
• tm248277d2_ex23-1.htm (EX-23.1) — 3KB
• tm248277d2_ex-filingfees.htm (EX-FILING FEES) — 50KB
• lg_biopathholdings-4clr.jpg (GRAPHIC) — 16KB
• 0001104659-24-032470.txt (&nbsp;) — 1075KB

RISK FACTORS

RISK FACTORS 7 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 10

USE OF PROCEEDS

USE OF PROCEEDS 12

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 15

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 17 PLAN OF DISTRIBUTION 20 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 26 INFORMATION INCORPORATED BY REFERENCE 26 i TABLE OF CONTENTS PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or in documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment decision. This prospectus includes or incorporates by reference information about this offering, our business and our financial and operating data. You should carefully read the entire prospectus, including under the sections titled "Risk Factors" included herein, and the documents incorporated by reference into this prospectus, before making an investment decision. Unless the context requires otherwise, references in this prospectus to "we," "our," "us," "the Company" and "Bio-Path" refer to Bio-Path Holdings, Inc. and its wholly-owned subsidiary. Bio-Path Holdings, Inc.'s wholly-owned subsidiary, Bio-Path, Inc., is sometimes referred to herein as "Bio-Path Subsidiary." Our Company We are a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize , is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize delivered antisense drug substances are sy

View Full Filing

View this S-1 filing on SEC EDGAR